Sunday, 25 June 2017

No heart risks from Novartis’ Parkinson’s drug

Good news for drug manufacturing company Norvatis as U.S. health regulators
said on Monday that they found
no evidence of increased
cardiovascular risks related to
Novartis AG's treatment, Stalevo,
for Parkinson's disease.

Norvatis are the manufacturer of the drug Stalevo which is used for
treating Parkinson's disease. The story would have been different if
the FDA have discovered that their drug linked to any cardiovascular
disease.

No comments:

Post a Comment

Fat, not carbs, is directly linked to weight gain

The research looked at mice on 30 different types of diets. The result of the research found that the mice on a high-fat, low-carb diet ga...